Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East
Virax Biolabs Group (NASDAQ: VRAX) has announced a distribution agreement for Mpox virus RT-PCR detection kits in 13 European countries and Gulf Cooperation Council (GCC) nations. The kits, which are CE-marked and authorized by the UK's MHRA, offer a sensitivity of 96.7% and specificity of 93.72%, delivering results in under 70 minutes.
CEO James Foster emphasized the company's commitment to providing healthcare professionals with tools to diagnose and mitigate Mpox spread. The agreement allows Virax to import, sell, and distribute Virax-branded Mpox virus Nucleic Acid Detection Kits in key European markets and GCC countries. Interested parties can contact Virax through their website for the Early Release Partnership Program (ERPP).
Il Gruppo Virax Biolabs (NASDAQ: VRAX) ha annunciato un accordo di distribuzione per i kit di rilevamento RT-PCR del virus Mpox in 13 paesi europei e nelle nazioni del Consiglio di Cooperazione del Golfo (GCC). I kit, che sono certificati CE e autorizzati dalla MHRA del Regno Unito, offrono una sensibilità del 96,7% e una specificità del 93,72%, fornendo risultati in meno di 70 minuti.
Il CEO James Foster ha sottolineato l'impegno dell'azienda a fornire agli operatori sanitari gli strumenti necessari per diagnosticare e mitigare la diffusione del Mpox. L'accordo consente a Virax di importare, vendere e distribuire i kit di rilevamento degli acidi nucleici del virus Mpox a marchio Virax nei principali mercati europei e nei paesi del GCC. Le parti interessate possono contattare Virax attraverso il loro sito web per il Programma di Partnership per il Rilascio Anticipato (ERPP).
El Grupo Virax Biolabs (NASDAQ: VRAX) ha anunciado un acuerdo de distribución para los kits de detección RT-PCR del virus Mpox en 13 países europeos y en las naciones del Consejo de Cooperación del Golfo (GCC). Los kits, que están marcados CE y autorizados por la MHRA del Reino Unido, ofrecen una sensibilidad del 96,7% y una especificidad del 93,72%, proporcionando resultados en menos de 70 minutos.
El CEO James Foster enfatizó el compromiso de la empresa de proporcionar a los profesionales de la salud herramientas para diagnosticar y mitigar la propagación del Mpox. El acuerdo permite a Virax importar, vender y distribuir kits de detección de ácidos nucleicos del virus Mpox de marca Virax en mercados clave europeos y países del GCC. Las partes interesadas pueden contactar a Virax a través de su sitio web para el Programa de Asociación de Lanzamiento Anticipado (ERPP).
Virax Biolabs 그룹 (NASDAQ: VRAX)가 13개 유럽 국가 및 걸프 협력 회의(GCC) 국가에서 Mpox 바이러스 RT-PCR 탐지 키트에 대한 유통 계약을 발표했습니다. 이 키트는 CE 인증을 받았으며 영국 MHRA의 승인을 받았으며, 96.7%의 민감도와 93.72%의 특이도를 제공하여 70분 이내에 결과를 제공합니다.
CEO 제임스 포스터는 Mpox 확산을 진단하고 완화하기 위한 도구를 의료 전문가에게 제공하겠다는 회사의 약속을 강조했습니다. 이 계약은 Virax가 주요 유럽 시장과 GCC 국가에서 Virax 브랜드 Mpox 바이러스 핵산 탐지 키트를 수입, 판매 및 배포할 수 있도록 합니다. 관심 있는 당사자는 조기 출시 파트너십 프로그램(ERPP)에 대해 Virax의 웹사이트를 통해 연락할 수 있습니다.
Le Groupe Virax Biolabs (NASDAQ: VRAX) a annoncé un accord de distribution pour les kits de détection RT-PCR du virus Mpox dans 13 pays européens et les nations du Conseil de coopération du Golfe (GCC). Les kits, qui sont marqués CE et autorisés par la MHRA du Royaume-Uni, offrent une sensibilité de 96,7% et une spécificité de 93,72%, fournissant des résultats en moins de 70 minutes.
Le PDG James Foster a souligné l'engagement de l'entreprise à fournir aux professionnels de la santé des outils pour diagnostiquer et atténuer la propagation du Mpox. L'accord permet à Virax d'importer, de vendre et de distribuer des kits de détection des acides nucléiques du virus Mpox de marque Virax sur des marchés européens clés et dans les pays du GCC. Les parties intéressées peuvent contacter Virax via leur site Web pour le Programme de partenariat de lancement anticipé (ERPP).
Die Virax Biolabs Group (NASDAQ: VRAX) hat eine Vertriebsvereinbarung für RT-PCR-Nachweiskits für das Mpox-Virus in 13 europäischen Ländern und den Mitgliedsstaaten des Golf-Kooperationsrates (GCC) bekannt gegeben. Die Kits, die CE-zertifiziert und von der MHRA des Vereinigten Königreichs autorisiert sind, bieten eine Empfindlichkeit von 96,7% und eine Spezifität von 93,72% und liefern Ergebnisse in weniger als 70 Minuten.
CEO James Foster betonte das Engagement des Unternehmens, Fachleuten im Gesundheitswesen Werkzeuge zur Diagnose und Minderung der Verbreitung von Mpox zur Verfügung zu stellen. Die Vereinbarung ermöglicht es Virax, Mpox-Virus-Nucleinsäure-Nachweiskits unter der Marke Virax in wichtigen europäischen Märkten und GCC-Ländern zu importieren, zu verkaufen und zu vertreiben. Interessierte Parteien können Virax über deren Website für das Early Release Partnership Program (ERPP) kontaktieren.
- Expansion into 13 European countries and GCC nations for Mpox virus detection kits
- CE-marked and MHRA-authorized kits with high sensitivity (96.7%) and specificity (93.72%)
- Quick results delivery in under 70 minutes
- Partnership with a leader in diagnostic reagents and equipment for infectious pathogens
- None.
Insights
The distribution agreement for Mpox RT-PCR detection kits marks a significant expansion of Virax Biolabs' market reach. The CE marking and MHRA authorization underscore the product's credibility, while the
However, it's important to note that Mpox cases have significantly declined since the 2022 outbreak peak. The long-term demand for these kits remains uncertain, especially given the availability of vaccines and improved awareness. The success of this venture will largely depend on Virax's ability to penetrate healthcare systems in the targeted countries and the potential for future outbreaks.
Virax's strategic move into 19 countries across Europe and the Middle East demonstrates a calculated approach to market expansion. The inclusion of GCC nations is particularly noteworthy, as these markets often have substantial healthcare budgets and a growing focus on advanced medical technologies.
However, investors should consider the competitive landscape. Major diagnostic players are already established in these markets and Virax will need to differentiate its offering. The Early Release Partnership Program could be a smart tactic to gain initial traction, but long-term success will hinge on pricing strategy, distribution efficiency and the company's ability to build lasting relationships with healthcare providers and government bodies in these diverse markets.
While this agreement expands Virax's potential revenue streams, investors should approach with cautious optimism. The financial impact will depend on volume of sales, pricing and profit margins, none of which were disclosed. Additionally, the costs associated with marketing, distribution and potential regulatory hurdles in multiple countries could be substantial.
Virax's stock (NASDAQ: VRAX) may see a short-term boost from this news, but sustainable growth will depend on the company's ability to translate this agreement into significant revenue. Given Virax's small market cap and the speculative nature of biotech stocks, investors should carefully consider their risk tolerance. Future financial reports will be important in assessing the real-world impact of this distribution agreement on Virax's bottom line.
The RT PCR Mpox virus detection kits are CE-marked for sale in
"Mpox virus poses a serious threat, and we continue to be committed to equipping healthcare professionals with the necessary tools to diagnose and mitigate its spread," James Foster, CEO of Virax Biolabs. "Our partnership with our suppliers, a leader in sales of diagnostic reagents and equipment related to infectious pathogens, underscores our commitment and enables us to reach at-risk communities across major geographies."
Under the terms of the agreement, Virax is authorized to import, sell and distribute Virax-branded Mpox virus Nucleic Acid Detection Kits in European countries including the
Potential interested parties in our Early Release Partnership Program ("ERPP") for the Mpox RT-PCR Detection kits can contact our sales representatives through our dedicated website www.viraxclear.com.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson and Adanna G. Alexander, Ph.D.
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-announces-distribution-agreement-to-commercialize-mpox-formerly-monkeypox-virus-rt-pcr-detection-kits-in-europe-and-the-middle-east-302232129.html
SOURCE Virax Biolabs
FAQ
What is the sensitivity and specificity of Virax Biolabs' Mpox virus RT-PCR detection kits?
In which countries will Virax Biolabs (VRAX) distribute the Mpox virus detection kits?
Are Virax Biolabs' (VRAX) Mpox virus detection kits approved for use in Europe?
How can interested parties access Virax Biolabs' (VRAX) Mpox virus detection kits?
